Stanford scientists cured Type 1 diabetes in a breakthrough experiment

Researchers at Stanford Medicine successfully cured Type 1 diabetes in mice by combining stem-cell and insulin-producing pancreatic cell transplants with low-dose radiation and immune-targeting drugs, avoiding graft-versus-host disease. The treatment created a hybrid immune system, allowing mice to regulate blood sugar without insulin injections or long-term immune-suppressing drugs, offering potential for future human therapies.
Researchers at Stanford Medicine announced a breakthrough in Type 1 diabetes treatment after curing the disease in mice through a novel approach. The method involved transplanting blood stem cells and insulin-producing pancreatic cells from donor animals while using low-dose radiation and immune-targeting drugs to weaken the mice’s harmful immune response. Unlike traditional transplants, this process avoided severe immune suppression and prevented graft-versus-host disease, a dangerous complication where donor immune cells attack the recipient’s organs. The goal was to reset the immune system, creating a hybrid system with a mix of donor and recipient cells. This allowed the mice to accept the new insulin-producing cells without rejection, eliminating the need for lifelong insulin injections or immune-suppressing medications during the study period. The study was led by Seung K. Kim, director of the Stanford Diabetes Research Center, with contributions from Preksha Bhagchandani and Stephan Ramos, building on earlier research by Judith Shizuru and the late Samuel Strober. The team addressed two key challenges: replacing damaged insulin-producing cells and preventing immune attacks on them. Previous Stanford research in 2022 successfully reversed chemically induced diabetes in mice, but the new study tackled autoimmune diabetes, where the immune system continuously targets beta cells—a condition closer to human Type 1 diabetes. The hybrid immune system approach showed promise for long-term acceptance of transplanted cells without severe side effects. The findings suggest potential applications beyond diabetes, including other autoimmune diseases and organ transplant complications. Researchers emphasized the gentler preparation process as a major advantage over traditional methods, which often rely on high-dose radiation or toxic drugs. The study builds hope for future clinical trials, though human testing remains a critical next step in translating these results into effective treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.